Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor

Giuseppe Deganutti, Kerry Barkan, Barbara Preti, Michele Leuenberger, Mark Wall, Bruno Frenguelli, Martin Lochner, Graham Ladds, Christopher A Reynolds

Research output: Other contribution

Abstract

Despite being amongst the most characterized G protein-coupled receptors (GPCRs), adenosine receptors (ARs) have always been a difficult target in drug design. To date, no agonist other than the natural effector and the diagnostic regadenoson has been approved for human use. Recently, the structure of the adenosine A1 receptor (A1R) was determined in the active, Gi protein complexed state; this has important repercussions for structure-based drug design. Here, we employed supervised molecular dynamics simulations and mutagenesis experiments to extend the structural knowledge of the binding of selective agonists to A1R. Our results identify new residues involved in the association and dissociation pathway, suggest the binding mode of N6-cyclopentyladenosine (CPA) related ligands, and highlight the dramatic effect that chemical modifications can have on the overall binding mechanism.
Original languageEnglish
TypePre-print
Media of outputOnline
PublisherbioRxiv
DOIs
Publication statusPublished - 22 Oct 2020

Bibliographical note

Made available under a CC-BY-NC-ND 4.0 International license.

Fingerprint Dive into the research topics of 'Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor'. Together they form a unique fingerprint.

Cite this